For questions regarding press and media, contact:
Skip Irvine, Director, Global Therapeutic Franchise Communications
267-305-5397

Merck Provides Update on the IMPROVE–IT Trial – 03/11/10

Merck said that it has submitted an update on Clinicaltrials.gov regarding the IMPROVE–IT trial – 01/07/10

Merck Statement on ARBITER 6–HALTS Study

Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN^® (ezetimibe/simvastatin) and ZETIA^® (ezetimibe)

Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN^® (ezetimibe/simvastatin) and
ZETIA^® (ezetimibe)

Merck and Schering-Plough to Merge

Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study – 03/30/08

Results from ENHANCE Study – 03/30/08

Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial – 01/25/08

ENHANCE Chronology – 01/25/08

Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial – 01/14/08

Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial – 11/19/07

Prescribing Information for VYTORIN^® (ezetimibe/simvastatin)
Patient Product Information for VYTORIN

Prescribing Information for ZETIA^® (ezetimibe)
Patient Product Information for ZETIA

To view PDF documents, you must have Adobe Reader installed on your computer.

This site is intended only for residents of the United States, its territories, and Puerto Rico.

VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. Other brands listed are the trademarks of their respective owners and are not trademarks of MSP Singapore Company, LLC.

Copyright © Merck/Schering-Plough Pharmaceuticals, 2002 - 2009.
All rights reserved.